| Literature DB >> 32047138 |
Sonja L Knowles1, Matthew E Mead2, Lilian Pereira Silva3, Huzefa A Raja1, Jacob L Steenwyk2, Gustavo H Goldman4, Nicholas H Oberlies5, Antonis Rokas6.
Abstract
Aspergillus fumigatus is a major opportunistic human pathogen. Multiple traits contribute to A. fumigatus pathogenicity, including its ability to produce specific secondary metabolites, such as gliotoxin. Gliotoxin is known to inhibit the host immune response, and genetic mutants that inactivate gliotoxin biosynthesis (or secondary metabolism in general) attenuate A. fumigatus virulence. The genome of Aspergillus fischeri, a very close nonpathogenic relative of A. fumigatus, contains a biosynthetic gene cluster that is homologous to the A. fumigatus gliotoxin cluster. However, A. fischeri is not known to produce gliotoxin. To gain further insight into the similarities and differences between the major pathogen A. fumigatus and the nonpathogen A. fischeri, we examined whether A. fischeri strain NRRL 181 biosynthesizes gliotoxin and whether the production of secondary metabolites influences the virulence profile of A. fischeri We found that A. fischeri biosynthesizes gliotoxin under the same conditions as A. fumigatus However, whereas loss of laeA, a master regulator of secondary metabolite production (including gliotoxin biosynthesis), has previously been shown to reduce A. fumigatus virulence, we found that laeA loss (and loss of secondary metabolite production) in A. fischeri does not influence its virulence. These results suggest that LaeA-regulated secondary metabolites are virulence factors in the genomic and phenotypic background of the major pathogen A. fumigatus but are much less important in the background of the nonpathogen A. fischeri Understanding the observed spectrum of pathogenicity across closely related pathogenic and nonpathogenic Aspergillus species will require detailed characterization of their biological, chemical, and genomic similarities and differences.IMPORTANCE Aspergillus fumigatus is a major opportunistic fungal pathogen of humans, but most of its close relatives are nonpathogenic. Why is that so? This important, yet largely unanswered, question can be addressed by examining how A. fumigatus and its close nonpathogenic relatives are similar or different with respect to virulence-associated traits. We investigated whether Aspergillus fischeri, a nonpathogenic close relative of A. fumigatus, can produce gliotoxin, a mycotoxin known to contribute to A. fumigatus virulence. We discovered that the nonpathogenic A. fischeri produces gliotoxin under the same conditions as those of the major pathogen A. fumigatus However, we also discovered that, in contrast to what has previously been observed in A. fumigatus, the loss of secondary metabolite production in A. fischeri does not alter its virulence. Our results are consistent with the "cards of virulence" model of opportunistic fungal disease, in which the ability to cause disease stems from the combination ("hand") of virulence factors ("cards") but not from individual factors per se.Entities:
Keywords: aspergillosis; evolution of virulence; fungal pathogenesis; gliotoxin; laeAzzm321990; secondary metabolism; specialized metabolism
Year: 2020 PMID: 32047138 PMCID: PMC7018655 DOI: 10.1128/mBio.03361-19
Source DB: PubMed Journal: mBio Impact factor: 7.867
FIG 1Aspergillus fischeri biosynthesizes gliotoxin when grown under conditions that induce A. fumigatus gliotoxin biosynthesis. (A) Chemical structure of gliotoxin. (B) The genome of the nonpathogenic species A. fischeri strain NRRL 181 (14, 28) contains a biosynthetic gene cluster homologous to the gliotoxin cluster in the major pathogen A. fumigatus strain Af293 (4–6). Arrows indicate genes and the direction in which they are transcribed. Homologous genes are connected by gray parallelograms. (C to I) Chromatograms demonstrating the biosynthesis of gliotoxin in A. fischeri when grown on CDA or blood agar at 37°C. Each sample (dried organic extract in MeOH at a concentration of 0.2 mg/ml) was analyzed by UHPLC-HRESIMS, and the data are presented as extracted ion chromatograms (XIC) using the protonated mass of gliotoxin (C13H15N2O4S2; [M+H]+ = 327.0473) and a window of ± 5.0 ppm. (C) Analysis of the gliotoxin standard (in MeOH at a concentration of 0.01 mg/ml). (D) A. fumigatus grown on CDA at 37°C. (E) A. fumigatus grown on blood agar at 37°C. (F) A. fischeri grown on CDA incubated at 37°C. (G) A. fischeri grown on blood agar incubated at 37°C. (H) A. fischeri grown on CDA at room temperature (RT). (I) A. fischeri grown on blood agar at RT. The retention time (3.30 min) and accurate mass (327.0473 ± 5.0 ppm) data confirm the biosynthesis of gliotoxin by A. fischeri in panels F and G. NL, normalization level (i.e., base peak intensity; the larger the NL value the better the signal to noise ratio).
FIG 2Deletion of the master regulator laeA in A. fischeri does not alter its virulence. Cumulative survivals of moth (Galleria mellonella) larvae inoculated with 5 × 105 (left) or 1 × 106 (right) asexual spores or conidia of either the ΔlaeA mutant or the wild-type (WT) A. fischeri NRRL 181 strain are shown. Comparisons of moth cumulative survival when infected with either the ΔlaeA or WT strain revealed no statistically significant differences at spore concentrations of 5 × 105 (left) or 1 × 106 (right) (P value = 0.91 and 0.30, respectively; log-rank test). For the inoculations, 10 moths were infected per group.